Gelesis Holdings Inc Quick Ratio (GLS) starting from the second quarter 2023 to second quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Gelesis Holdings Inc   (GLS)

Gelesis Holdings Inc 's Quick Ratio

GLS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Gelesis Holdings Inc 's Cash & cash equivalent grew by 154.88 % in the Q2 2023 sequentially, faster than Current Liabilities, this led to improvement in Gelesis Holdings Inc 's Quick Ratio to 0.1, Quick Ratio remained below Gelesis Holdings Inc average.

Within Major Pharmaceutical Preparations industry 543 other companies have achieved higher Quick Ratio than Gelesis Holdings Inc in second quarter 2023. While Quick Ratio total ranking in the second quarter 2023 has deteriorated compared to the prior quarter from 3813 to 4345.

Explain Quick Ratio?
How much Cash & cash equivalents GLS´s has?
What are GLS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GLS Quick Ratio (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2
Y / Y Current Liabilities Change 118.52 % 200.34 % 477.52 % 2791.16 % 1536.55 %
Y / Y Cash & cash equivalent Change -68.79 % -90.87 % -73.9 % 8048.05 % 3101.23 %
Quick Ratio MRQ 0.1 0.04 0.09 0.31 0.72
GLS's Total Ranking # 4345 # 3813 # 4149 # 3153 # 2404
Seq. Current Liabilities Change 0.47 % -3.43 % -1.14 % 127.82 % 38.09 %
Seq. Cash & cash equivalent Change 154.88 % -58.14 % -70.17 % -1.95 % -25.43 %



Quick Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 544
Healthcare Sector # 1065
Overall Market # 4345


Quick Ratio Statistics
High Average Low
39343.55 3026.74 0.01
(Sep 30 2020)   (Dec 31 2021)




Financial Statements
Gelesis Holdings Inc 's Current Liabilities $ 77 Millions Visit GLS's Balance sheet
Gelesis Holdings Inc 's Cash & cash equivalent $ 8 Millions Visit GLS's Balance sheet
Source of GLS's Sales Visit GLS's Sales by Geography


Cumulative Gelesis Holdings Inc 's Quick Ratio

GLS's Quick Ratio for the trailling 12 Months

GLS Quick Ratio

 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth 305.42 % 514.44 % 952.92 % 1652.75 % 1176.46 %
Y / Y Cash & cash equivalent TTM Growth -50.84 % -4.37 % 200.86 % 4338.38 % 2510.32 %
Quick Ratio TTM 0.14 0.22 0.42 0.73 1.15
Total Ranking TTM # 4615 # 3430 # 4231 # 2660 # 3098
Seq. Current Liabilities TTM Growth 15.38 % 23.2 % 42.4 % 100.29 % 74.87 %
Seq. Cash & cash equivalent TTM Growth -28.72 % -33.72 % -18.64 % 27.88 % 38.67 %

Quick ratio ranking by company, industry and sector >> Back to GLS Financial Strength Comparisons >> Go to Compare GLS Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2023 to $76.54 millions, cumulative Quick Ratio decreased to 0.14 below the Gelesis Holdings Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 578 other companies have achieved higher Quick Ratio than Gelesis Holdings Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2023 from 3430 to 4615.

Explain Quick Ratio?
How much Cash & cash equivalents GLS´s has?
What are GLS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 579
Healthcare Sector # 1165
Within the Market # 4615


trailing twelve months Quick Ratio Statistics
High Average Low
0.36 0.19 0.03
(Sep 30 2022)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2023 MRQ Cash & cash equivalentJun 30 2023 MRQ Current Liabilities
Avalo Therapeutics Inc   0.28 $ 6.322  Millions$ 22.454  Millions
Merck and Co Inc   0.27 $ 6,378.000  Millions$ 23,394.000  Millions
Integrated Biopharma Inc  0.27 $ 1.316  Millions$ 4.828  Millions
Abbvie Inc   0.27 $ 8,766.000  Millions$ 32,239.000  Millions
Lexaria Bioscience Corp   0.26 $ 0.270  Millions$ 1.024  Millions
Societal Cdmo Inc   0.26 $ 4.703  Millions$ 18.214  Millions
Ernexa Therapeutics Inc   0.26 $ 1.837  Millions$ 7.165  Millions
Catalent Inc   0.25 $ 280.000  Millions$ 1,120.000  Millions
Supernus Pharmaceuticals inc   0.24 $ 24.706  Millions$ 103.764  Millions
Checkpoint Therapeutics inc   0.23 $ 7.421  Millions$ 31.608  Millions
Grifols Sa  0.23 $ 593.126  Millions$ 2,593.476  Millions
Kamada Ltd   0.21 $ 21.788  Millions$ 102.639  Millions
Avenue Therapeutics Inc   0.20 $ 1.571  Millions$ 7.812  Millions
Palatin Technologies Inc   0.20 $ 2.993  Millions$ 15.132  Millions
Ibio inc   0.20 $ 4.351  Millions$ 22.109  Millions
Intelgenx Technologies Corp   0.19 $ 2.225  Millions$ 11.597  Millions
Molecular Templates Inc   0.18 $ 4.952  Millions$ 26.937  Millions
Agile Therapeutics Inc  0.18 $ 2.785  Millions$ 15.309  Millions
Tiziana Life Sciences Ltd  0.18 $ 1.183  Millions$ 6.539  Millions
Eagle Pharmaceuticals inc   0.18 $ 15.354  Millions$ 86.630  Millions
Biofrontera Inc   0.18 $ 4.453  Millions$ 25.352  Millions
Scienture Holdings Inc   0.17 $ 0.746  Millions$ 4.263  Millions
Lunai Bioworks Inc   0.17 $ 1.874  Millions$ 10.830  Millions
Eli Lilly And Company  0.15 $ 2,829.100  Millions$ 18,915.000  Millions
Keenova Therapeutics Plc  0.15 $ 480.600  Millions$ 3,255.300  Millions
Amneal Pharmaceuticals Inc   0.15 $ 114.582  Millions$ 777.350  Millions
NIKA PHARMACEUTICALS, INC  0.15 $ 0.011  Millions$ 0.076  Millions
Evelo Biosciences Inc   0.14 $ 7.622  Millions$ 52.851  Millions
Promis Neurosciences inc   0.14 $ 1.254  Millions$ 8.739  Millions
Astrazeneca Plc  0.14 $ 6,504.000  Millions$ 45,834.000  Millions

Date modified: 2026-09-08T15:11:02+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.